Pediatric Vaccines Market, Share, Global Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis
Global Pediatric Vaccines Market is expected to reach USD 62 Billion in 2027. In this huge market of vaccines Pediatric Vaccines for Coronavirus account for a significant market share. Over the years, Pediatric vaccination has made a tremendous public health success story. The lives of billions of children have been saved, and millions have the chance of a longer, healthier life, a more significant opportunity to learn, play, read and write, and move around freely without suffering. Besides, in the 21st century, the development, licensing, and implementation of Pediatric vaccines as part of large, systematic immunization programs have also addressed global health inequities. Therefore, imagining a world without vaccines would be life-threatening, with diseases presenting daily risk.
Impact of COVID-19 on Global Pediatric Vaccines Market
With the emergence of the SARS-CoV-2 virus in December 2019 and its potential for global dissemination to cause COVID-19 disease was realized, there was an urgent need to develop vaccines at an unprecedented rate and scale for the particular pandemic. Hence, amidst the pandemic, the global market for Pediatric vaccines declined in 2020 as most of the healthcares personal were busy in COVID-19 management.
However, the Pediatric vaccines market size has shown tremendous growth for the year 2021. All thanks to the COVID-19 vaccines approval for children in few western countries. Furthermore, as we appreciate and quantify the health, economic and social benefits of Pediatric vaccines and immunization programs to individuals and society. We endeavour to see the Global Pediatric Vaccine Industry to register a CAGR of 4.4% during the forecast period of 2021-2027.
Numbers of Vaccinated Pediatric (Infants) Remains Variable
At the same time, access to Pediatric vaccines that prevent life-threatening infectious diseases remains variable to all infants around the world. Further, to eradicate such problems, numerous individuals and agencies are working hard to address them globally. Recently, the development of safe and efficacious vaccination against diseases that cause substantial morbidity and mortality has been a significant scientific advance. Vaccination, sanitation, and clean drinking water are public health interventions that are undeniably responsible for improved infant health outcomes globally.
For instance, agencies including the United Nations Children's Fund (UNICEF), World Health Organization (WHO), Gavi, The Bill & Melinda Gates Foundation, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Initiative (CEPI), with their multiple funding streams have been instrumental in expanding vaccine benefits to all.
Worldwide Pediatric Vaccines Market Size was US$ 47.8 Billion for 2021
The global pediatric vaccines market is robust and has successfully reached enormous potential. Hence, pediatric vaccines are among tremendous advances in global health and development. Besides, pediatric vaccines have safely reduced the scourge of diseases like Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella, helping children grow up healthy and happy. Remarkably, with immunization efforts worldwide, children can walk, play, dance and learn. Today, vaccines are expected to be one of the most cost-effective means of advancing global welfare.
Major Players in Global Pediatric Vaccines Market
The Pediatric vaccines market consists of several major players, including GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited. Notwithstanding, the key players of pediatric vaccines are broad and far-reaching, though not consistently quantifiable, analyzed or communicated. However, an increasing appreciation for vaccines' economic and social effects is being included in the development of the new vaccine, potentially realizing a more significant benefit to society and resulting in broader implementation by the companies.
Renub Research latest report “Pediatric Vaccines Market, Global Forecast By Disease Wise (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Crop (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTaP, Hib (Haemophilus Influenza Type B), Combos (Combination Vaccines), Polio, Rotavirus and Varicella), Products and Pipeline (GSK Vaccine Product Pipeline, Merck Vaccine Product Pipeline, Sanofi Vaccine Product Pipeline and Pfizer Vaccine Product Pipeline), Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Key Players Sales (GlaxoSmithKline, Merck & Co, Sanofi Pasteur's, Pfizer, Inc. and Thoracic Aortic Aneurysm (TAA)CSL Limited)” provides a detailed analysis of Pediatric Vaccines Industry.
Disease wise – Pediatric (Infants) Vaccines Market have been covered from 12 viewpoints:
1. Coronavirus (COVID-19)
2. Influenza
3. MMR (Measles, Mumps, and Rubella Vaccine)
4. Pneumococcal
5. Meningococcal
6. Hepatitis
7. DTaP
8. Haemophilus Influenzae Type B (HIB)
9. Combos (Combination)
10. Polio
11. Rotavirus
12. Varicella
Disease wise – Numbers of Vaccinated Pediatric (Infants) have been covered from 12 viewpoints:
1. Coronavirus (COVID-19)
2. Influenza
3. MMR (Measles, Mumps, and Rubella Vaccine)
4. Pneumococcal
5. Meningococcal
6. Hepatitis
7. DTaP
8. Haemophilus Influenzae Type B (HIB)
9. Combos (Combination)
10. Polio
11. Rotavirus
12. Varicella
By Regions – Pediatric (Infants) Vaccines Market and Number have been covered from 5 viewpoints:
1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East and Africa
Vaccines – Products and Pipeline have been covered from 4 viewpoints:
1. GSK Vaccine Product Pipeline
2. Merck Vaccine Product Pipeline
3. Sanofi Vaccine Product Pipeline
4. Pfizer Vaccine Product Pipeline
Company Insight:
• Overview
• Recent Development
• Sales Analysis
Vaccines Key Players Sales have been covered from 5 viewpoints:
1. GlaxoSmithKline, Plc
2. Merck & Co.
3. Sanofi Pasteur’s
4. Pfizer, Inc.’s
5. CSL Limited
- 1. Introduction
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Dynamics
- 4.1 Growth Driver
- 4.2 Challenges
- 5. Pediatric (Infant) Vaccines Market
- 6. Pediatric Vaccinated Numbers
- 7. Market & Numbers Share – Pediatric Vaccine Analysis
- 7.1 Pediatric Vaccine Market Share
- 7.2 Pediatric Vaccinated Population Share
- 7.3 By Regions Market share
- 8. Disease wise – Pediatric (Infants) Vaccines Market
- 8.1 Influenza
- 8.2 MMR (Measles, Mumps, and Rubella Vaccine)
- 8.3 Pneumococcal
- 8.4 Meningococcal
- 8.5 Hepatitis
- 8.6 DTaP
- 8.7 Haemophilus Influenzae Type B (HIB)
- 8.8 Combos (Combination)
- 8.9 Polio
- 8.10 Rotavirus
- 8.11 Varicella
- 9. Disease wise – Numbers of Vaccinated Pediatric (Infants)
- 9.1 Influenza
- 9.2 MMR
- 9.3 Pneumococcal
- 9.4 Meningococcal
- 9.5 Hepatitis
- 9.6 DTaP
- 9.7 Hib (Haemophilus Influenzae Type B)
- 9.8 Combos (Combination Vaccines)
- 9.9 Polio
- 9.10 Rotavirus
- 9.11 Varicella
- 10. By Region– Pediatric (Infants) Vaccines Market and Number
- 10.1 North America
- 10.1.1 Market
- 10.1.2 Number
- 10.2 Europe
- 10.2.1 Market
- 10.2.2 Number
- 10.3 Asia Pacific
- 10.3.1 Market
- 10.3.2 Number
- 10.4 Latin America
- 10.4.1 Market
- 10.4.2 Number
- 10.5 Middle East and Africa
- 10.5.1 Market
- 10.5.2 Number
- 11. Mergers and Acquisitions in the Vaccine Industry
- 12. Vaccines and Regulator’s Interventions
- 12.1 Making and Meeting Standards of Quality and Safety
- 12.2 Vaccine Funding
- 13. Vaccines – Products and Pipeline
- 13.1 GSK Vaccine Product Pipeline
- 13.2 Merck Vaccine Product Pipeline
- 13.3 Sanofi Vaccine Product Pipeline
- 13.4 Pfizer Vaccine Product Pipeline
- 14. Porters Five Forces
- 14.1 Overview
- 14.2 Bargaining Power of Buyers
- 14.3 Bargaining Power of Suppliers
- 14.4 Degree of Competition
- 14.5 Threat of New Entrants
- 14.6 Threat of Substitutes
- 15. Company Analysis
- 15.1 GlaxoSmithKline, plc.
- 15.1.1 Overview
- 15.1.2 Recent Development
- 15.1.3 Sales Analysis
- 15.2 Merck & Co.
- 15.2.1 Overview
- 15.2.2 Recent Development
- 15.2.3 Sales Analysis
- 15.3 Sanofi Pasteur’s
- 15.3.1 Overview
- 15.3.2 Recent Development
- 15.3.3 Sales Analysis
- 15.4 Pfizer, Inc.’s
- 15.4.1 Overview
- 15.4.2 Recent Development
- 15.4.3 Sales Analysis
- 15.5 CSL Limited
- 15.5.1 Overview
- 15.5.2 Recent Development
- 15.5.3 Sales Analysis
- List Of Figures:
- Figure-01: Global Pediatric (Infant) Vaccines Market (Million US$), 2016 – 2021
- Figure-02: Global – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2022 – 2027
- Figure-03: Global – Pediatric (Infant) Vaccines Number (Million), 2016 – 2021
- Figure-04: Global – Forecast for Pediatric (Infant) Vaccines Number (Million), 2022 – 2027
- Figure-05: Disease wise – Influenza Market (Million US$), 2016 – 2021
- Figure-06: Disease wise – Forecast for Influenza Market (Million US$), 2022 – 2027
- Figure-07: Disease wise – MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2016 – 2021
- Figure-08: Disease wise – Forecast for MMR (Measles, Mumps, and Rubella Vaccine) Market (Million US$), 2022 – 2027
- Figure-09: Disease wise – Pneumococcal Market (Million US$), 2016 – 2021
- Figure-10: Disease wise – Forecast for Pneumococcal Market (Million US$), 2022 – 2027
- Figure-11: Disease wise – Meningococcal Market (Million US$), 2016 – 2021
- Figure-12: Disease wise – Forecast for Meningococcal Market (Million US$), 2022 – 2027
- Figure-13: Disease wise – Hepatitis Market (Million US$), 2016 – 2021
- Figure-14: Disease wise – Forecast for Hepatitis Market (Million US$), 2022 – 2027
- Figure-15: Disease wise – DTaP Market (Million US$), 2016 – 2021
- Figure-16: Disease wise – Forecast for DTaP Market (Million US$), 2022 – 2027
- Figure-17: Disease wise – Haemophilus Influenzae Type B (HIB) Market (Million US$), 2016 – 2021
- Figure-18: Disease wise – Forecast for Haemophilus Influenzae Type B (HIB) Market (Million US$), 2022 – 2027
- Figure-19: Disease wise – Combos (Combination) Market (Million US$), 2016 – 2021
- Figure-20: Disease wise – Forecast for Combos (Combination) Market (Million US$), 2022 – 2027
- Figure-21: Disease wise – Polio Market (Million US$), 2016 – 2021
- Figure-22: Disease wise – Forecast for Polio Market (Million US$), 2022 – 2027
- Figure-23: Disease wise – Rotavirus Market (Million US$), 2016 – 2021
- Figure-24: Disease wise – Forecast for Rotavirus Market (Million US$), 2022 – 2027
- Figure-25: Disease wise – Varicella Market (Million US$), 2016 – 2021
- Figure-26: Disease wise – Forecast for Varicella Market (Million US$), 2022 – 2027
- Figure-27: Disease wise – Influenza Number (Million), 2016 – 2021
- Figure-28: Disease wise – Forecast for Influenza Number (Million), 2022 – 2027
- Figure-29: Disease wise – MMR Number (Million), 2016 – 2021
- Figure-30: Disease wise – Forecast for MMR Number (Million), 2022 – 2027
- Figure-31: Disease wise – Pneumococcal Number (Million), 2016 – 2021
- Figure-32: Disease wise – Forecast for Pneumococcal Number (Million), 2022 – 2027
- Figure-33: Disease wise – Meningococcal Number (Million), 2016 – 2021
- Figure-34: Disease wise – Forecast for Meningococcal Number (Million), 2022 – 2027
- Figure-35: Disease wise – Hepatitis Number (Million), 2016 – 2021
- Figure-36: Disease wise – Forecast for Hepatitis Number (Million), 2022 – 2027
- Figure-37: Disease wise – DTaP Number (Million), 2016 – 2021
- Figure-38: Disease wise – Forecast for DTaP Number (Million), 2022 – 2027
- Figure-39: Disease wise – Hib (Haemophilus Influenzae Type B) Number (Million), 2016 – 2021
- Figure-40: Disease wise – Forecast for Hib (Haemophilus Influenzae Type B) Number (Million), 2022 – 2027
- Figure-41: Disease wise – Combos (Combination Vaccines) Number (Million), 2016 – 2021
- Figure-42: Disease wise – Forecast for Combos (Combination Vaccines) Number (Million), 2022 – 2027
- Figure-43: Disease wise – Polio Number (Million), 2016 – 2021
- Figure-44: Disease wise – Forecast for Polio Number (Million), 2022 – 2027
- Figure-45: Disease wise – Rotavirus Number (Million), 2016 – 2021
- Figure-46: Disease wise – Forecast for Rotavirus Number (Million), 2022 – 2027
- Figure-47: Disease wise – Varicella Number (Million), 2016 – 2021
- Figure-48: Disease wise – Forecast for Varicella Number (Million), 2022 – 2027
- Figure-49: GlaxoSmithKline, plc.’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-50: GlaxoSmithKline, plc.’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-51: Merck & Co. Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-52: Merck & Co. Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-53: Sanofi Pasteur’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-54: Sanofi Pasteur’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-55: Pfizer, Inc.’s Vaccines Sales – Global Revenue (Million US$), 2016 – 2021
- Figure-56: Pfizer, Inc.’s Vaccines Sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- Figure-57: Thoracic Aortic Aneurysm (TAA)CSL Limited sales – Global Revenue (Million US$), 2016 – 2021
- Figure-58: Thoracic Aortic Aneurysm (TAA)CSL Limited sales – Forecast for Global Revenue (Million US$), 2022 – 2027
- List Of Tables:
- Table-01: Global – Pediatric Vaccines Market Share (Percent), 2016 – 2021
- Table-02: Global – Forecast for Pediatric Vaccines Market Share (Percent), 2022 – 2027
- Table-03: Global – Pediatric Vaccines Population Share (Percent), 2016 – 2021
- Table-04: Global – Forecast for Pediatric Vaccines Population Share (Percent), 2022 – 2027
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook